Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $153.1 million.

  • Inhibrx Biosciences' Cash & Equivalents fell 22.02% to $153.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.1 million, marking a year-over-year decrease of 22.02%. This contributed to the annual value of $152.6 million for FY2024, which is 45.09% down from last year.
  • Latest data reveals that Inhibrx Biosciences reported Cash & Equivalents of $153.1 million as of Q3 2025, which was down 17.95% from $186.6 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Cash & Equivalents registered a high of $277.9 million during Q4 2023, and its lowest value of $152.6 million during Q4 2024.
  • For the 3-year period, Inhibrx Biosciences' Cash & Equivalents averaged around $201.4 million, with its median value being $196.3 million (2024).
  • Data for Inhibrx Biosciences' Cash & Equivalents shows a maximum YoY tumbled of 45.09% (in 2024) over the last 5 years.
  • Over the past 3 years, Inhibrx Biosciences' Cash & Equivalents (Quarterly) stood at $277.9 million in 2023, then tumbled by 45.09% to $152.6 million in 2024, then dropped by 22.02% to $153.1 million in 2025.
  • Its last three reported values are $153.1 million in Q3 2025, $186.6 million for Q2 2025, and $216.5 million during Q1 2025.